Highest-materiality recent filing
RemeGen gets NMPA nods for telitacicept in IgAN and Sjögren’s; Vor Bio holds ex-China rights
First BAFF/APRIL-targeting therapy approved for IgA nephropathy; conditional NMPA approval based on Phase 3 TELIGAN trial showing 55% placebo-adjusted UPCR reduction.
Vor Biopharma raises $75M via private placement with TCGX for telitacicept development
Gross proceeds of $75M from sale of 5.34M shares at $14.05/share to TCGX affiliates.
Vor Biopharma Chief Development Officer Qing Zuraw departs Dec 31; gets $565K severance + consulting
Dr. Qing Zuraw, Chief Development Officer, resigned effective Dec 31, 2025 to pursue other opportunities.
Vor Bio raises $150M in private placement; appoints two new directors
Private placement of 13.9M shares at $10.81 for gross proceeds of ~$150M.
Vor Biopharma reprices employee stock options to $8.18; CEO gets 4.16M options repriced
Board reduced exercise price of ~5.2M underwater options to $8.18, the Dec 5, 2025 closing price.
10,000,000 shares at $10.00 each; expected net proceeds ~$93.7M (or $107.8M if underwriters' option fully exercised).
Vor Bio appoints Jeremy Sokolove CMO; amends CDO severance terms
Dr. Jeremy Sokolove appointed CMO effective Nov 3, 2025; has >20 yrs rheumatology/autoimmune R&D experience.
Vor Biopharma reports 48-week Phase 3 data for telitacicept in Sjögren's disease from China
Webcast held Oct 28, 2025 to discuss late-breaking 48-week Phase 3 results from China.
Stockholders approved reverse stock split in range 1-for-5 to 1-for-30; board to determine ratio.
Vor Bio appoints Qing Zuraw as CDO, Michel Detheux and Bo Cumbo as directors
Resignation of director Sven (Bill) Ante Lundberg effective July 17, 2025; no disagreement cited.
Vor Biopharma appoints Sandesh Mahatme as CFO and Chief Business Officer
Sandesh Mahatme appointed CFO, Principal Financial Officer and Principal Accounting Officer, effective July 9, 2025.
Vor Bio licenses telitacicept from RemeGen for $125M upfront, raises $175M PIPE, appoints new CEO
License deal: Vor Bio gets ex-China rights to telitacicept (global Phase 3 for gMG) for $125M upfront ($45M cash + $80M warrants); up to $4B+ milestones plus royalties.
Vor Bio winds down operations, cuts 95% of staff, and explores sale or merger
Board approved wind-down of clinical and manufacturing operations; workforce reduced by 147 employees (~95%).
Vor Biopharma receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule
Notice received April 22, 2025; stock below $1.00 for 30 consecutive business days.
Chief Medical Officer Eyal Attar resigns effective April 18, 2025
Eyal C. Attar, M.D., resigned as Chief Medical Officer of Vor Biopharma, effective April 18, 2025.
Vor Bio appoints Erez Kalir to board, filling new seat linked to Reid Hoffman-led PIPE
Board expanded from 7 to 8 members; Kalir designated by Reprogrammed Interchange (Hoffman entity).
Vor Bio raises $55.6M in PIPE; extends cash runway to 2025 clinical data readouts
Private placement of 55.87M shares and warrants for 69.84M shares at combined $0.99425 price, gross proceeds ~$55.6M.
Preliminary data shows median RFS not reached after 7.4 months follow-up in 15 AML patients treated with trem-cel + Mylotarg.
Vor Bio reports positive trem-cel + Mylotarg data; plans pivotal trial
Phase 1/2 VBP101: 18 patients received trem-cel; 10 received Mylotarg as of July 19, 2024 cut-off.
Vor Biopharma receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Vor Biopharma on Aug 29, 2024 that its common stock bid price has been below $1.00 for 30 consecutive business days.
Vor Biopharma CFO Nathan Jorgensen resigns; CEO Ang named interim principal financial officer
Nathan Jorgensen resigns as CFO effective June 21, 2024, to pursue a new opportunity; no disagreement cited.
VBP101 (trem-cel) abstract accepted for oral at ASH; shows robust neutrophil engraftment and hematologic protection from Mylotarg.
Vor Bio reports engraftment data from 5 AML patients in trem-cel study; FDA clears VCAR33 ALLO IND
All 5 trem-cel patients achieved neutrophil engraftment in 10-11 days; high myeloid donor chimerism at day 28.
First AML patient maintained neutrophil and platelet counts ~5 months post trem-cel transplant through three Mylotarg doses at 0.5 mg/m².
Vor Bio reports initial clinical proof-of-concept for trem-cel; first AML patient engrafts normally
First patient received trem-cel dose of 7.6x10^6 CD34+ cells/kg with 88% CD33 editing efficiency.
Vor Biopharma prices $115.8M combined stock offering and private placement at $4.30/share
15.3M shares sold in underwritten offering for gross $65.8M; 11.6M shares in private placement to RA Capital for $50M.
Vor Biopharma presented at Piper Sandler 34th Annual Healthcare Conference on November 29, 2022.
On July 6, 2026, Andrew Levin, M.D., Ph.D., a member of the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”), delivered his notice of resignation, effective immediately.
On July 7, 2026, the Board appointed David Zaccardelli, Pharm.D. to the vacancy created by Dr. Levin’s resignation, to serve on the Board as an independent Class II director until the Company’s 2029 annual meeting of stockholders and until his successor is duly elected and qualified or his earlier resignation or removal.
On May 19, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s principal financial officer and principal accounting officer.
on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.
on May 8, 2025, the Company terminated the employment of Han Choi as Chief Financial Officer and Tirtha Chakraborty, PhD as Chief Scientific Officer and Head of Technical Operations, effective as of May 16, 2025 (the “Separation Date”), without cause.
On March 31, 2025, Eyal C. Attar, M.D., notified Vor Biopharma Inc. (the “Company”) of his decision to resign as Chief Medical Officer of the Company, effective as of April 18, 2025, in order to pursue a new opportunity.
On January 6, 2025 the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) increased the size of the Board from seven to eight members and appointed Erez Kalir to fill the resulting vacancy, to serve on the Board as an independent Class III director until the Company’s 2027 annual meeting of stockholders and until his successor is duly elected and qualified.
On September 30, 2024, Vor Biopharma Inc. (the “Company”) announced that the board of directors (the “Board”) has appointed Han Choi, M.D., LL.M., as Chief Financial Officer of the Company, effective as of September 30, 2024 (the “Effective Date”).
On June 8, 2024, the Board designated Robert Ang, M.B.B.S., M.B.A., the Company’s President and Chief Executive Officer and a director of the Company, as the Company’s interim principal financial officer
and Amy Quinlan, the Company’s Vice President of Finance, as the Company’s interim principal accounting officer, effective as of the Effective Date.
On June 4, 2024, Nathan Jorgensen, Ph.D., M.B.A., notified Vor Biopharma Inc. (the “Company”) of his resignation as Chief Financial Officer of the Company, effective as of June 21, 2024 (the “Effective Date”), in order to pursue a new opportunity.
On April 30, 2024, the Board of Directors (the “Board”) of Vor Biopharma Inc. (the “Company”) increased the size of the Board from six to seven members and appointed Fouad Namouni, M.D., to fill the resulting vacancy, to serve on the Board as an independent Class II director, until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified.
Max materiality 0.90 · Median 0.60 · Most common event other_material